Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05997017 · ClinicalTrials.gov registry record · Phase 2
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
A Phase 2 study of Cancer and Endometrial Cancer, sponsored by Aadi Bioscience.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 9
- Study locations
NCT05997017: Recruiting Phase 2 study of Cancer and Endometrial Cancer, sponsored by Aadi Bioscience.
NCT05997017 is a Phase 2 study of Cancer and Endometrial Cancer that is actively recruiting participants, run by Aadi Bioscience. The registered enrollment target is 29 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 9 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05997017, a Phase 2 study of Cancer and Endometrial Cancer, is actively recruiting participants, sponsored by Aadi Bioscience.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 9
- Study locations
Study Summary
A Phase 2 Multi-center Open-label Trial of nab-Sirolimus in Combination with Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer
Primary Outcome
ORR, defined as the proportion of patients with best overall response (BOR) of confirmed partial response (PR) or complete response (CR) from the time of study treatment initiation until progression of disease (PD) as determined by the Investigator using RECIST v1.1.
Conditions Studied
Interventions
- DRUG nab-sirolimus
Study Locations (9)
Arkansas
- Michael Birrer, MD, PhD - Little Rock
Florida
- Mount Sinai Comprehensive Cancer Center - Miami Beach
Nevada
- Women's Cancer Center of Nevada - Las Vegas
New York
- Memorial Sloan Kettering Cancer Center - New York
North Carolina
- Levine Cancer Institute - Charlotte
Oklahoma
- Oklahoma University Stephenson Cancer Center - Oklahoma City
Rhode Island
- Women & Infants Hospital - Providence
Texas
- Texas Oncology - Tyler - Tyler
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2023-12-28 |
| Est. Completion | 2027-06 |
| Phase | Phase 2 |
What NCT05997017 shows while recruiting
NCT05997017 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower).
The record links to 6 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which nab-sirolimus is the first listed.
NCT05997017 lists 9 locations in 9 states (Arkansas, Florida, Nevada).
Frequently Asked Questions
What is clinical trial NCT05997017 about?
NCT05997017 is a clinical study titled "Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer". A Phase 2 Multi-center Open-label Trial of nab-Sirolimus in Combination with Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer
What is the current status of trial NCT05997017?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2023-12-28. Estimated completion is 2027-06.
What conditions does trial NCT05997017 study?
This clinical trial studies the following conditions: Cancer, Endometrial Cancer, Recurrent Endometrial Carcinoma, Tumor, Endometrioid Endometrial Cancer.
What interventions are being tested in trial NCT05997017?
The interventions under investigation include: nab-sirolimus (DRUG).
Who is sponsoring clinical trial NCT05997017?
This trial is sponsored by Aadi Bioscience, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05997017 being conducted?
This trial has 9 study locations across Arkansas, Florida, Nevada, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05997017's enrollment target sits among peer trials
29 524th of 615 higher than 89 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
CAncer TReatment INformed by the Molecular Tumor Board At Dartmouth
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Acupuncture for People Experiencing Period Loss Due to Chemotherapy
RECRUITING · Phase 2
-
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI